The consumer goods corporation reported fiscal Q2 2022 earnings figures that topped estimates
Procter & Gamble (P&G) revealed an EPS of $1.66 slightly higher than the $1.65 expected for the quarter ended in December. Net sales rose 6% to $20.95 billion, surpassing the $20.34 billion forecasted. At the same time, organic revenue also rose 6%. Approximately half of the growth was due to the rising prices of various products.
According to the company's executives, more price increases are underway, and retailers have already discussed the matter. Some additions are to take effect on February 28 and mid-April.
For the ongoing fiscal year, P&G revised its sales growth forecast of 4% - 5% from a previous range of 2% - 4% upwards. It also plans to boost the buyback program from last year's high of $9 billion to as much as $10 billion. P&G didn't change the forecast for earnings, confirming that it sees core figures growing 3%-6% from $5.66 per share reported in 2021.
After the news hit the wires, P&G's share price traded 4.25% higher at $163.50 apiece, pushing its six-month gain to 17%.
Sources: cnbc.com, thestreet.com
This information is prepared for general circulation. It does not regard to the specific investment objectives, financial situation or the particular needs of any recipient.
You should independently evaluate each financial product and consider the suitability of such a financial product, by taking into account your specific investment objectives, financial situation or particular needs, and by consulting an independent financial adviser as needed, before dealing in any financial products mentioned in this document.
This information may not be published, circulated, reproduced or distributed in whole or in part to any other person without the Company’s prior written consent. Past performance is not always indicative of likely or future performance. Any views or opinions presented are solely those of the author and do not necessarily represent those of za.capex.com
JME Financial Services (Pty) Ltd trading as ZA.CAPEX.COM acts as intermediary between the investor and Magnasale Trading Ltd, the counterparty to the contract for difference purchased by the Investor via ZA.CAPEX.COM, authorised & regulated by the Cyprus Securities and Exchange Commission with license number 264/15. Magnasale Trading Ltd is the principal to the CFD purchased by investors.